Stay updated with breaking news from Edication Pricing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biogen's chief executive officer on Thursday said the company wants a dialogue with the CMS ahead of a final decision on coverage of its controversial Alzheimer's disease drug in April.
For patients with metastatic melanoma, triplet therapy with atezolizumab and vemurafenib plus cobimetinib provides significant survival benefits, but the regimen may not be cost-effective, researchers say.